Future directions in pragmatic and hybrid trial designs with RWE elements Future Directions in Pragmatic and Hybrid Trial Designs with RWE Elements Introduction to Real-World Evidence (RWE) and Its Importance in FDA Submissions Real-World Evidence (RWE) has emerged as an important element in the FDA regulatory framework, particularly in the context of drug development and post-market surveillance. RWE refers to the clinical evidence derived from the analysis of Real-World Data (RWD) – data that are collected from a variety of sources outside the confines of traditional clinical trials. These sources include electronic health records (EHRs), insurance claims data, and patient…

Implementation Checklists for High Quality RWE Study Execution The establishment of high-quality Real-World Evidence (RWE) is critical for regulatory submissions to the FDA, especially as these evidence types gain traction in informing clinical decisions and regulatory actions. This tutorial will explore the essential checklists and methodologies necessary for executing RWE studies that meet the expectations of the FDA and other international regulatory bodies. Professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and data standards will find this guide particularly valuable. Understanding the Need for RWE in Regulatory Submissions RWE is derived from data collected outside of traditional…

Bridging RCT and RWE Evidence for Robust Benefit-Risk Assessments The integration of randomized controlled trial (RCT) data and real-world evidence (RWE) is becoming increasingly vital for regulatory submissions and decision-making in the pharmaceutical and medical devices sectors. This tutorial provides a step-by-step guide on how to effectively design RWE studies that meet FDA requirements and bridge this critical gap in evidence generation for benefit-risk assessments. Understanding FDA Regulations and Guidelines for RWE The FDA has recognized the importance of RWE in complementing traditional RCTs. According to the FDA’s framework for incorporating RWE in regulatory submissions, RWE can demonstrate the effectiveness…

Working with KOLs, Regulators, and Statisticians on RWE Methodology Real-World Evidence (RWE) is becoming increasingly pivotal in regulatory decision-making. As regulatory authorities like the US FDA actively encourage the use of RWE in assessing the safety and effectiveness of medical products, understanding how to collaborate with Key Opinion Leaders (KOLs), regulators, and statisticians in developing robust RWE study design methodology is essential. This tutorial will guide you in navigating these collaborations effectively, focusing specifically on FDA submissions, while referencing UK and EU practices where applicable. Understanding Real-World Evidence (RWE) in the Regulatory Landscape The FDA defines RWE as the clinical…

Pre-specifying RWE Protocols and SAPs for Regulatory Transparency In the evolving landscape of pharmaceutical regulation, the significance of Real-World Evidence (RWE) has grown, particularly regarding regulatory submissions to the U.S. Food and Drug Administration (FDA). Developing robust RWE study design methodologies for FDA submissions is essential for ensuring effective regulatory compliance and securing approval. This article serves as a comprehensive guide for regulatory, biostatistics, Health Economics and Outcomes Research (HEOR), RWE, and data standards professionals in the pharmaceutical and medtech industries. Understanding Regulatory Expectations for RWE The FDA has increasingly highlighted the role of RWE in the drug approval process,…